Magnetic resonance techniques to monitor the long term evolution of multiple sclerosis pathology and to monitor definitive clinical trials

Journal of Neurology Neurosurgery and Psychiatry

Volumn 64, Issue SUPPL. 1, 1998, Pages

  Paty, D W ^a,c   McFarland, H ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Axonal loss; Clinical trials; Magnetic resonance imaging; Multiple sclerosis evolution

Indexed keywords

CONFERENCE PAPER; DISEASE COURSE; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATIENT MONITORING; PRIORITY JOURNAL; RELAPSE;

AXONS; BRAIN; CLINICAL TRIALS; DEMYELINATING DISEASES; DISEASE PROGRESSION; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; TIME FACTORS;

EID: 0031779731     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (27)

1. Noakes JB, Herkes GK, Frith JA, et al. Magnetic resonance imaging in clinically-definite multiple sclerosis. Med J Aust 1990;152:136-40.
2. Paty DW. Magnetic resonance imaging in the assessment of disease activity in multiple sclerosis. Can J Neurol Sci 1988;15:266-72.
3. Smith ME, Martin R, Frank JA, et al. Gadolinium-enhanced magnetic resonance imaging and its correlation with expanded disability status score in multiple sclerosis. Ann Neurol 1991;30:270.
4. Thompson AJ, Youl B, Feinstein A, et al. Serial enhanced MRI in early relapsing/remitting and benign multiple sclerosis. Neurology 1991;41:169.
5. Filippi M, Barker GJ, Horsfield MA, et al. Benign and secondary progressive multiple sclerosis: a preliminary quantitative MRI study. J Neurol 1994;241:246-51.
6. Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991;29:53-62.
7. Kermode AG, Tofts PS, Thompson AJ, et al. Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. Neurology 1990;40:229-35.
8. Willoughby EW, Grochowski E, Li DKB, et al. Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients. Ann Neurol 1989; 25:43-9.
9. Koopmans RA, Li DKB, Oger JJF, et al. Chronic progressive multiple sclerosis: serial magnetic resonance brain imaging over six months. Ann Neurol 1989;26:248-56.
10. Dousset V, Brochet B, Gaillou A, et al. Longitudinal magnetization transfer study of MS lesions. 10th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, San Francisco, Book of Abstracts. San Francisco: ECTRMS, 1994:49.
11. MacKay AL, Whittall KP, Cover KS, et al. In vivo T2 relaxation measurements of brain may provide myelin concentration. Society of Magnetic Resonance in Medicine, 10th Annual Meeting, San Francisco, Book of Abstracts. San Francisco: SMRM, 1991;2:917.
12. Wolinsky JS, Narayana PA, Jackson EF, et al. Localized proton magnetic resonance spectroscopy (MRS) in multiple sclerosis (MS): correlation with gadolinium-DTPA enhanced MRI. Neurology 1991;41:169.
13. Arnold DL, Matthews PM, Francis GS, et al. Proton MR spectroscopic imaging (SI) for metabolic characterization of the brain plaques of demyelinating disease. Neurology 1991;41:144.
14. Stewart WA, Hall LD, Berry K, et al. Magnetic resonance imaging (MRI) in multiple sclerosis (MS): pathological correlation studies in eight cases. Neurology 1986;36: 320.
15. Stewart WA. Proton spin relaxation as a means of characterizing the pathology of multiple sclerosis [dissertation]. Vancouver, BC: University of British Columbia, 1989.
16. Barnes D, Munro PM, Youl BD, et al. The longstanding MS lesion: a quantitative MRI and electron microscopic study. Brain 1991;114:1271-80.
17. Katz D, Taubenberger JK, Canella B, et al. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 1993;34:661-9.
18. Nesbit GM, Forbes GS, Scheithauer BW, et al. Histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy. Radiology 1991;180: 467-74.
19. Newcombe J, Hawkins CP, Henderson CL, et al. Histopathology of multiple sclerosis lesions detected by magnetic resonance imaging in unfixed postmortem central nervous system tissue. Brain 1991;114:1013-3.
20. 1-weighted) spin-echo images. Neurology 1995;45:1684-90.
21. Stone LA, Albert PS, Smith ME, et al. Changes in the amount of diseased white matter over time in patients with relapsing-remitting multiple sclerosis. Neurology 1995;45:1808-14.
22. Jacobs L, Cookfair D, Rudick RA, et al. Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-94.
23. Moreau T, Thorpe J, Miller D, et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. 10th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Book of Abstracts. San Francisco: ECTRMS, 1994:45.
24. Paty DW, Li DKB, UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43: 662-7.
25. Stone L, Smith ME, Frank JA, et al. Incidence of contrast enhancement on MRI over time in MS patients. Neurology 1994;44:A391.
26. Dousset V, Grossman RI, Ramer KN, et al. Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging. Radiology 1992;182:483-91.
27. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon β-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-85.